in past times several years, the united kingdom has witnessed a revolution in clinical excess weight‑reduction solutions — through the introduction of semaglutide (Wegovy®) on the developing reputation of tirzepatide (Mounjaro®). Now, An additional title is drawing interest in the two clinical an